To further validate the critical role of Pik3 cd and Ifngr1 in the anti‐tumor immune effects of FAST therapy, we carried out the inhibition of PI3Kδ in leukocytes and IFNγR in tumor cells. The gene discussed is IFNGR1; the disease is neoplasm.